U.S. Markets closed

Stoke Therapeutics shares soar 46% in trading debut

Ciara Linnane

Stoke Therapeutics Inc. shares rocketed 46% in their trading debut Wednesday, after the company's initial public offering priced above its $14 to $16 price range. The company sold 7.9 million shares priced at $18 each to raise $142 million. Proceeds of the deal will be used to advance clinical trials of its lead product candidate STK-001, a treatment for the severe form of epilepsy Dravet syndrome. JPMorgan, Cowen, Credit Suisse and Canaccord were underwriters on the deal.